Our Group Senior Management Team.

  • Danny Yeung
    Danny Yeung Co-Founder & Chief Executive Officer

    Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

    Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

    Danny Yeung Co-Founder & Chief Executive Officer
  • Stephen Lo
    Stephen Lo Chief Financial Officer

    Stephen has served as the Chief Financial Officer of Prenetics since 2018, and oversees the financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis and investor relations. Prior to joining Prenetics, Mr. Lo was in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the U.S. between 2014 and 2018. From 2007 to 2011, Mr. Lo was an auditor with Ernst & Young.

    Mr. Lo received a Master of Business Administration from Yale University’s School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science and a bachelor’s degree in Accounting from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the Institute of Chartered Accountants in England and Wales and a CFA Charterholder.

    Stephen Lo Chief Financial Officer
  • Dr.Lawrence
    Dr.Lawrence Tzang, PhD Co-Founder And Chief Scientific Officer

    Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014. Dr. Tzang oversees development, evaluation and implementation of new testing products and services, supervision of laboratory setup and operation and governance of medical laboratory accreditation.

    Dr. Tzang has over 18 years industry experience in diagnostic testing and is recognized as a leader in DNA-based molecular diagnostic techniques. Dr. Tzang has been a registered Medical Laboratory Technologist I at Board of Medical Laboratory Technologist since 2013, a founding member and secretary at the Hong Kong Society for Behavioral and Neural Genetics since 2011 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his post-doctoral research fellowship at Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009.

    Dr. Tzang received a Ph.D. in Molecular Biology and a B.Sc. in Applied Chemistry from the City University of Hong Kong in 2003 and 1996, respectively.

    Dr.Lawrence Tzang, PhD Co-Founder And Chief Scientific Officer
  • Joel Neoh
    Joel Neoh Chief Consumer Officer

    Joel Neoh is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. Joel’s experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, Joel was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Joel has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, Joel was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, Joel headed up its Asia Pacific business, overseeing more than 2,000 employees. Joel’s entrepreneurial journey started out by co-founding Says.com, one of Malaysia’s largest digital news platforms. Joel is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance. His entrepreneurial success and leadership led to his recognition as Ernst & Young Emerging Entrepreneur of the Year (Malaysia) in 2012, and as a Young Global Leader by the World Economic Forum in 2013.

    Joel Neoh Chief Consumer Officer
  • Peter Wong
    Dr. Peter Wong, DPHIL Chief Technology Officer
    Dr. Peter Wong is the Chief Technology Officer of Prenetics. Since he joined in 2017, Dr. Wong has been leading Prenetics’ global technology vision and roadmap, and engineering delivery. Prior to Prenetics, Dr. Wong was the Head of Engineering at Travelex, where he led Travelex’s first digital transformation and B2B business. Dr. Wong also successfully delivered a brand new international money transfer service, Travelex Wire, and launched Travelex’s first international payment platform with the World Bank Group. Dr. Wong has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events including AWS Summit and various universities. Dr. Wong holds a Doctorate degree in Computer Science from the University of Oxford, and B.Sc. and M.Sc. degrees in Computer Science from the University of Warwick.
    Dr. Peter Wong, DPHIL Chief Technology Officer
  • Senthil Sundaram
    Dr. Senthil Sundaram, MD Chief Clinical Officer
    Dr. Senthil Sundaram is the Chief Clinical Officer of Prenetics, and is responsible for overseeing the clinical policies. Dr. Sundaram is highly recognised for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works were funded by the National Institute of Health (NIH), USA. Dr. Sundaram also served as a reviewer of different journals and NIH study sections.
    Dr. Senthil Sundaram, MD Chief Clinical Officer
  • Dr. Frank S. Ong, MD
    Dr. Frank S. Ong, MD Chief Medical Officer

    Dr. Frank Ong, MD. Chief Medical Officer for Prenetics is a seasoned industry-leading physician-scientist in Clinical Development (Certified Principal Investigator, Certified Clinical Research Professional, Medical Monitor) and Medical Affairs with clinical fellowship specialization in medical genetics and sub-specialization in clinical molecular genomics laboratory testing for hereditary oncology, common and rare hereditary adult and pediatric conditions, pharmacogenetics, carrier screening, and women's health. Prior to joining Prenetics as Group Chief Medical Officer, Dr. Ong was the Chief Medical Officer and Chief Scientific Officer of Everly Health and held previous leadership roles in Guardant Health, Illumina and Roche. Dr. Ong led the first FDA 510(k) cleared NGS-based assay and NGS platform in 2013 as well as the first at-home COVID test to obtain Emergency Use Authorization by the US FDA in 2020.

    Dr. Ong received his Medical Doctorate at the Keck School of Medicine of the University of Southern California in 2002, and completed his residency and fellowship at the University of California, Los Angeles and Cedars-Sinai Medical Center before serving on the faculty at Cedars-Sinai Medical Center.

    Dr. Frank S. Ong, MD Chief Medical Officer
  • Samantha Kwok
    Samantha Kwok Vice President People & Culture

    Samantha Kwok is the VP of People & Culture of Prenetics, and is responsible for all the overall people strategy, global talent acquisition, leadership development, organizational design, and delivering an inclusive employee and candidate experience which reflects Prenetics vision, mission and values. Samantha works with leaders across Prenetics’ different lines of business to support their dynamic needs, and is focused on developing and implementing strategies which drive business results and foster a positive and creative work environment. Prior to Prenetics, Samantha had extensive recruitment and HR consulting experience across Greater China, advising and consulting for many of China’s largest tech companies including Alibaba, VIPKID, Didi, Bytedance, Binance and Xiaomi, Daimler and FGS Global through her own entrepreneurial ventures. Samantha was also Chief of Staff, People and Operations at multiple tech startups, consumer brands and B2B platforms, helping several international brands launch and expand successfully throughout APAC. Samantha holds a degree in political, economic and social sciences from the University of Sydney.

    Samantha Kwok Vice President People & Culture

Our Business Unit Management Team.

  • Danny Yeung
    Danny Yeung Chief Executive Officer of Insighta

    Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

    Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

    Danny Yeung Chief Executive Officer of Insighta
  • Joel Neoh
    Joel Neoh Managing Director of CircleDNA

    Joel Neoh is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. Joel’s experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, Joel was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Joel has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, Joel was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, Joel headed up its Asia Pacific business, overseeing more than 2,000 employees. Joel’s entrepreneurial journey started out by co-founding Says.com, one of Malaysia’s largest digital news platforms. Joel is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance. His entrepreneurial success and leadership led to his recognition as Ernst & Young Emerging Entrepreneur of the Year (Malaysia) in 2012, and as a Young Global Leader by the World Economic Forum in 2013.

    Joel Neoh Managing Director of CircleDNA
  • Walt Ling
    Walt Ling Chief Executive Officer of ACT Genomics

    Mr. Walt Ling is the Chief Executive Officer of ACT Genomics Co., Ltd. He has over 25 years of experience in the medical device industry with a broad base of management and operational experience covering strategy, sales, marketing, finance, clinical applications, technical service and human resources.

    Prior to joining ACT Genomics, Mr. Ling was the Vice President and Managing Director APAC for Oxford Immunotec, a company focused on infectious disease solutions. During his tenure at Oxford Immunotec, he was responsible for executing regional commercial operations and business expansion strategies. Mr. Ling was also responsible for the regional integration efforts in the recent acquisition of the company by PerkinElmer. Prior to Oxford Immunotec, Mr. Ling was the Vice President and Managing Director APAC for Leica Biosystems, a medical device company that develops and supplies clinical diagnostics to the pathology market.

    Mr. Ling received a Masters of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University and a Bachelors of Business Administration degree from the University of Texas at Austin. Mr. Ling is a member of the Singapore Chapter of the Young Presidents Organization.

    Mr. Ling received a Masters of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University and a Bachelors of Business Administration degree from the University of Texas at Austin. Mr. Ling is a member of the Singapore Chapter of the Young Presidents Organization.

    Walt Ling Chief Executive Officer of ACT Genomics

Our Scientific Advisory Board.

  • Prof. Tony S. K. Mok
    Prof. Tony S. K. Mok

    Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc, and an independent director of HUTCHMED (China) Limited. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

    Prof. Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and have played a significant role in defining current practice. Prof. Mok has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.

    Prof. Tony S. K. Mok
  • Pasi
    Prof. Pasi A. Jänne, MD, PhD

    Prof. Pasi Jänne is a globally renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science. Prof. Jänne's research combines laboratory-based study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer. He has made seminal therapeutic discovery including co-discovery of EGFR mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.

    Prof. Pasi Jänne's translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC. Prof. Jänne has received multiple awards for his work including from the AACR, ESMO and ASCO.

    Prof. Pasi A. Jänne, MD, PhD
  • Prof. Pan-Chyr Yang, PhD
    Prof. Pan-Chyr Yang, PhD

    Prof. Yang is the former President of Taiwan University and has been a professor in the department of internal medicine at the College of Medicine for 27 years. He has also served as the Director of the Advisory Office for the Ministry of Education and as Dean for the College of Medicine at Taiwan University. Dr. Yang was honoured with the Joseph W. Cullen Prevention/Early Detection Award at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

    Prof. Yang is a pioneer and leader in pulmonary ultrasound diagnostics and therapeutics that have revolutionized the management of pulmonary diseases which include lung cancer. He has led a research group to develop the method for detection and quantification circulating cancer cells in peripheral blood and to better predict the prognosis and response to treatment for lung cancer patients. He has led a research group to discover novel genes and pathways that are associated with lung cancer pathogenesis and progression. They identified specific gene expression and microRNA signatures that can assist to predict the treatment outcome and may be beneficial for personalized therapy of lung cancer patients.

    Prof. Pan-Chyr Yang, PhD
  • Dr.Lawrence
    Dr.Lawrence Tzang, PhD

    Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014. Dr. Tzang oversees development, evaluation and implementation of new testing products and services, supervision of laboratory setup and operation and governance of medical laboratory accreditation.

    Dr. Tzang has over 18 years industry experience in diagnostic testing and is recognized as a leader in DNA-based molecular diagnostic techniques. Dr. Tzang has been a registered Medical Laboratory Technologist I at Board of Medical Laboratory Technologist since 2013, a founding member and secretary at the Hong Kong Society for Behavioral and Neural Genetics since 2011 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his post-doctoral research fellowship at Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009.

    Dr. Tzang received a Ph.D. in Molecular Biology and a B.Sc. in Applied Chemistry from the City University of Hong Kong in 2003 and 1996, respectively.

    Dr.Lawrence Tzang, PhD
  • Dr. Frank S. Ong, MD
    Dr. Frank S. Ong, MD

    Dr. Frank Ong, MD. Chief Medical Officer for Prenetics is a seasoned industry-leading physician-scientist in Clinical Development (Certified Principal Investigator, Certified Clinical Research Professional, Medical Monitor) and Medical Affairs with clinical fellowship specialization in medical genetics and sub-specialization in clinical molecular genomics laboratory testing for hereditary oncology, common and rare hereditary adult and pediatric conditions, pharmacogenetics, carrier screening, and women's health. Prior to joining Prenetics as Group Chief Medical Officer, Dr. Ong was the Chief Medical Officer and Chief Scientific Officer of Everly Health and held previous leadership roles in Guardant Health, Illumina and Roche. Dr. Ong led the first FDA 510(k) cleared NGS-based assay and NGS platform in 2013 as well as the first at-home COVID test to obtain Emergency Use Authorization by the US FDA in 2020.

    Dr. Ong received his Medical Doctorate at the Keck School of Medicine of the University of Southern California in 2002, and completed his residency and fellowship at the University of California, Los Angeles and Cedars-Sinai Medical Center before serving on the faculty at Cedars-Sinai Medical Center.

    Dr. Frank S. Ong, MD
  • Dr. Hua-Chien Chen, PhD
    Dr. Hua-Chien Chen, PhD

    Dr. Hua Chien Chen is the Co-founder and the Chief Scientific Officer of ACT Genomics. He has more than 20 years of experience in cancer biology, genomics and drug discovery. Dr. Hua Chien Chen earned his PhD in Biochemistry from National Yang-Ming University in Taiwan and completed his postdoctoral training in Molecular Biology at Case Western Reserve University in the USA.

    In 1998, Dr Hua Chien Chen was an Assistant Investigator at the National Health Research Institute, where he worked on the discovery and development of molecular targets for new drugs. Dr. Chen then joined TaiGen Biotechnology as the Biology Director, where he oversaw the drug screening program. From 2006 to 2014, Dr. Chen took up a position as Associate Professor at Chang Gung University, where he established a multiplexed micro-RNA quantification platform for the Molecular Medicine Research Center. This platform was developed to identify non-invasive biomarkers for cancer and other diseases. Dr. Hua Chien Chen has extensive experience in the biotech industry, technology-based project evaluation and license negotiation. Dr. Chen is also an accomplished scientist and acknowledged expert in the fields of molecular biology, oncology and genomics.

    Dr. Hua-Chien Chen, PhD